Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Cash & Current Investments (2016 - 2025)

Bioceres Crop Solutions' Cash & Current Investments history spans 7 years, with the latest figure at $11.7 million for Q2 2024.

  • For Q2 2024, Cash & Current Investments fell 80.59% year-over-year to $11.7 million; the TTM value through Jun 2025 reached $11.7 million, changed N/A, while the annual FY2024 figure was $11.7 million, 80.59% down from the prior year.
  • Cash & Current Investments for Q2 2024 was $11.7 million at Bioceres Crop Solutions, down from $60.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $60.3 million in Q2 2023 and bottomed at $11.7 million in Q2 2024.
  • The 5-year median for Cash & Current Investments is $38.9 million (2022), against an average of $39.5 million.
  • The largest annual shift saw Cash & Current Investments surged 546.57% in 2020 before it plummeted 80.59% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $50.3 million in 2020, then dropped by 27.48% to $36.5 million in 2021, then increased by 6.59% to $38.9 million in 2022, then skyrocketed by 55.01% to $60.3 million in 2023, then tumbled by 80.59% to $11.7 million in 2024.
  • Per Business Quant, the three most recent readings for BIOX's Cash & Current Investments are $11.7 million (Q2 2024), $60.3 million (Q2 2023), and $38.9 million (Q2 2022).